Ignite Creation Date:
2024-05-06 @ 4:45 PM
Last Modification Date:
2024-10-26 @ 2:16 PM
Study NCT ID:
NCT05086692
Status:
RECRUITING
Last Update Posted:
2024-03-29
First Post:
2021-09-10
Brief Title:
A Beta-only IL-2 ImmunoTherapY Study
Sponsor:
Medicenna Therapeutics Inc
Organization:
Medicenna Therapeutics Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Advanced Solid Tumor |
| Unresectable Solid Tumor |
| Clear Cell Renal Cell Carcinoma |
| Triple Negative Breast Cancer |
| Non-Small Cell Lung Cancer Squamous |
| Non-Small Cell Lung Cancer Non-squamous |
| Colorectal Cancer MSI-H |
| Gastric Cancer |
| Cervical Cancer |
| Basal Cell Carcinoma |
| Bladder Cancer |
| Merkel Cell Carcinoma |
| Squamous Cell Carcinoma of Head and Neck |
| Cutaneous Squamous Cell Carcinoma |
| Pleural Mesothelioma |
| Esophageal Cancer |
| Endometrial Carcinoma |
| Solid Tumor |
| Solid Tumor Adult |
| MSI-H Solid Malignant Tumor |
| Cancer With A High Tumor Mutational Burden |
| Epithelial Ovarian Carcinoma |
| Primary Peritoneal Cancer |
| Gastroesophageal Junction GEJ Cancer |
| Acral Melanoma |
| Mucosal Melanoma |
| Cutaneous Melanoma |
| Fallopian Tube Cancer |
| Ovarian Cancer |
| MSI-H Cancer |
| DMMR Cancer |
| Pancreas Adenocarcinoma MSI-H |
| DMMR Solid Malignant Tumor |
| Skin Cancer |
Keywords:
| Name | View |
|---|---|
| IL-2 | View |
| IL2 | View |
| Interleukin-2 | View |
| cancer | View |
| metastatic | View |
| ccRCC | View |
| TNBC | View |
| NSCLC | View |
| CRC | View |
| GEJ | View |
| intrahepatic | View |
| extrahepatic | View |
| MCC | View |
| SCCHN | View |
| CSCC | View |
| Gastroesophageal Junction | View |
| advanced | View |
| unresectable | View |
| MSI-H | View |
| dMMR | View |
| Microsatellite Instability-High | View |
| Mismatch Repair Deficient | View |
| PD-1 | View |
| immunotherapy | View |
| anti-PD-1 | View |
| BCC | View |
| RCC | View |
| HCC | View |
| Tumor Mutation Burden High | View |
| TMB-H | View |
| PDAC | View |